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Objectives: Adding bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF), to
platinum-based chemotherapy/pemetrexed in 1st line treatment of advanced malignant
pleural mesothelioma (MPM), significantly improved overall survival. However, increased
high grade bleeding after operation was reported in patients with colorectal cancer who
previously received bevacizumab. In the present analysis, we assessed for the first time
the impact of adding bevacizumab to induction chemotherapy prior to surgery for
mesothelioma patients.
Methods: Two hundred twenty-seven MPM patients, intended to be treated with
induction chemotherapy followed by surgery at the University Hospital of Zurich
between 2002 and December 2018, were included in the present analysis. After
propensity score matching for gender, histology and age (1:3 ratio), data from 88
patients were analyzed. Sixty-six patients underwent induction chemotherapy (with cis-/
carboplatin and pemetrexed: control group) alone and 22 patients underwent induction
chemotherapy with the addition of bevacizumab (bevacizumab group) prior macroscopic
complete resection (MCR). Perioperative and long-term outcome variables were analyzed.
Results: Patients undergoing combination treatment with bevacizumab had a
significantly better response than with chemotherapy alone as assessed by modified
RECIST (p=0.046). Intraoperative complications in the bevacizumab group (one patient),
or in the control group (three patients) were not related to intraoperative bleeding.
Postoperative transfusion of blood products occurred in a larger amount in the control
group than in the bevacizumab group (p=0.047). Overall survival was not statistically
different between both groups.
Conclusion: These initial data demonstrate that MCR can be performed safely after triple
induction chemotherapy with bevacizumab without increased intra- and postoperative
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bleeding complications. Response rates were significantly improved by the addition of
bevacizumab.
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INTRODUCTION
Malignant pleural mesothelioma (MPM) is an aggressive cancer
with poor outcome despite multimodality treatment (1, 2). The
Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS)—a
multicenter, randomized, controlled, clinical phase III trial-
showed the improvement of survival by the addition of
bevacizumab to standard chemotherapy cisplatin/carboplatin/
pemetrexed in first line treatment for advanced MPM (survival
18.8 months [95% CI 15.9-22.6] vs. 16.1 months [95% CI 14.0–
17.9]) (3).
Vascular endothelial growth factor (VEGF) represents a
target for cancer treatment as anti-VEGF agents can induce a
direct toxicity by decreasing neoplastic cell viability. Moreover
they induce structural changes on tumor vasculature with
increase in stability, perfusion and permeability leading to an
augmented distribution of chemotherapeutic agents at the tumor
site (4). A previous meta-analysis of 20 randomized controlled
trials reported an overall increase in high grade bleeding in
colorectal, renal and non-small cell lung cancer, as well as an
increase in thrombotic events (5–7) in patients undergoing
treatment with anti-VEGF agents.
OBJECTIVES
In the present analysis, we report for the first time, the
perioperative and long-term outcome as well as chemotherapy
response when bevacizumab is added to current standard
platinum based induction chemotherapy for MPM patients
undergoing subsequent macroscopic complete resection (MCR).
PATIENTS AND METHODS
This is an observational study of retrospective nature. The
institutional database was searched for patients intended to be
treated with induction chemotherapy followed by surgery
(n=227) during the period 2002–2018. Some patients in both
groups (bevacizumab and control group) were treated within our
phase I and II trials of intracavitary application of cisplatin
bound to a fibrin carrier (NCT01644994). Sixty-six patients were
excluded due to missing data (n=35) or palliative therapy only
(n=31). Propensity score matching (1:3 ratio), was performed in
161 patients based on age, gender, and histotype (see Table 1)
between patients receiving induction chemotherapy (cisplatin/
carboplatin/pemetrexed) with bevacizumab and induction
chemotherapy (cisplatin/carboplatin/pemetrexed) (control
group) followed by surgery. Follow-up was performed with
computed tomography (CT) and positron emission
tomography/computed tomography (PET/CT) scans in an
alternating manner according to our institutional guidelines.
This means a post-surgery quarterly clinical and radiological
follow-up within the 1st year, bi-annual in the 2nd year, and from
there on annually. A logistic regression model was fitted to
obtain the propensity score with the application of
bevacizumab as outcome and the three explanatory variables
mentioned above to reduce potential sources of bias. The
standardized mean difference was used to estimate the group
differences, which is preferred over the sample size dependent t-
test (see Table 1). The matching was performed without
repetition of controls and a caliper distance within 0.2 times
the standard deviation of the propensity scores was accepted as a
match. For all cases obtaining bevacizumab three appropriate
matches were found.
For statistical analysis, R-software version 3.5.3 was used.
Continuous variables were analyzed with paired t-test and
conditional logistic regression was performed for binary
variables. A p value of <0.05 was considered as statistically
significant. Missing data are reflected in the overall column in
each table. Throughout the manuscript, due to the missing
adjustment for multiple testing in this analysis, p values should
be interpreted as descriptive.
Local ethics committee approval was given for analysis of the
mesothelioma database (StV 29-2009, EK-ZH 2012-0094).
Staging and Induction Chemotherapy
Mesothelioma was diagnosed and staged as described previously
(8). After completion of staging, patients received between two and
seven cycles of induction chemotherapy either with cisplatin/
carboplatin or carboplatin/pemetrexed with the addition of
bevacizumab in 22 cases. In case of only two cycles applied, the
chemotherapy was interrupted due to side effects and the patient
proceeded to surgery. In case of seven cycles (n=1), the patient did
not want to undergo surgery at first and decided at a later point to
have surgery. The last cycle prior to surgery was conducted without
bevacizumab. The decision for induction chemotherapy with the
addition of bevacizumab was individually discussed for each patient
at our interdisciplinary tumor-board based on the comorbidity
profile of the patient (e.g. coagulation disorders).
Surgery and Intraoperative Blood Loss
Thirty-one patients underwent (extended) pleurectomy/
decortication [(E)PD), 35 extrapleural pneumonectomy (EPP)]
in the control group whereas in the bevacizumab group 21
patients underwent (E)PD and one patient EPP. P/D only was
performed in four patients in the control group and none in the
bevacizumab group. EPP and (E)PD were performed as already
Lauk et al. Bevacizumab Prior Pleural Mesothelioma Surgery
Frontiers in Oncology | www.frontiersin.org November 2020 | Volume 10 | Article 5885632
described previously (8). The difference between EPD and P/D
was that in EPD pericardium and/or diaphragm are additionally
resected depending on the tumor spread. In uncertain cases this
was decided under guidance of intraoperatively taken fresh
frozen sections.
Blood loss during surgery as well as the amount of substituted
erythrocyte concentrates were documented.
Further, hemoglobin, hematocrit and thrombocytes were
measured on postoperative day (POD) 1 to 6; not all values
were available for each day. Thirty- and 90-day mortality was
reported as well as postoperative morbidity. Postoperative major
morbidity included: complications necessitating reoperation,
chylothorax, patch failure, empyema, bronchopleural fistula,
thromboembolic events, and acute respiratory distress
syndrome (ARDS). The number of thromboembolic events for
each patient are reported in detail, in particular the time point of
the events (before chemotherapy, after chemotherapy but before
surgery, post-surgery and after adjuvant chemo-/radiotherapy).
mRECIST
Chemotherapy response was assessed by mRECIST in a restaging
CT scan (9). The p-value was calculated via a McNemar test.
OS and PFS
Overall survival (OS) and progression free survival (PFS) probabilities
were calculated with Kaplan Meier analysis and the difference
between treatment groups was evaluated with a conditional long
rank test. The median and 95% confidence interval were also
determined using the Kaplan-Meier method. OS was calculated
from start of induction chemotherapy until death or lost to follow up.
RESULTS
88 patients, receiving either induction chemotherapy (cisplatin/
carboplatin/pemetrexed + bevacizumab) or induction chemotherapy
(platinum based/pemetrexed) only, followed by surgery, were
analyzed (Figure 1): 66 patients in the control group and 22
patients in the bevacizumab group [(see Table 1) after propensity
score matching (1:3 ratio)]. Additionally, intracavitary
chemotherapy was applied in nine patients of the control
group and six patients of the bevacizumab group. Patient`s
characteristics are shown in Table 2.
The overall median age in this present cohort was 65 years
(range 40–76 years) and did not differ significantly between both
groups. All patients underwent surgery in a median time of 41.5
days (6 weeks, range 15–155 days) after the last cycle of
induction chemotherapy. The median number of cycles applied
for all patients was 3 (range 2–7). One patient had surgery <20
days following the last cycle of chemotherapy based on his own
wish. Two patients underwent surgery after >100 days; one due
to other surgery and the other based on patient’s wishes.
mRECIST
According to mRECIST criteria (9) there were no patients
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compared to 15 patients (22.7%) with PD in the control group
following induction chemotherapy. Partial remission (PR)
was observed in 23 cases in the control group (34.8%) and
nine cases (40.9%) in the bevacizumab group. 28 cases (42.4%)
in the control and 13 cases (59.1%) in the bevacizumab group,
had stable disease (SD). The overall response rate was
significantly better in the bevacizumab group with a p-value
of 0.046.
FIGURE 1 | Postoperative hemoglobin, hematocrit, erythrocyte, and thrombocyte values from day 1–6. POD, postoperative day.
TABLE 2 | Patients’ characteristics.
Covariate Overall Control group Bevacizumab group p-value
n 88 66 22
Age (median [range]) 65 [40-76] 65 [40-76] 64.5 [50-76] NS
Gender, male (%) 71 (80.7) 53 (80.3) 18 (81.8) NS
Laterality of MPM, right (%) 53 (60.2) 37 (56.1) 16 (72.7) NS
Epithelioid histotype (%) 73 (83.0) 55 (83.3) 18 (81.8) NS
Induction chemotherapy
Cisplatin (%) 78 (88.6) 60 (90.9) 18 (81.8) NS
Carboplatin (%) 18 (20.5) 11 (16.7) 7 (31.8) NS
Pemetrexed (%) 87 (98.9) 65 (98.5) 22 (100.0) NS
Bevacizumab (%) 22 (25.0) 0 (0.0) 22 (100.0) <0.001
Other (%) 1 (1.1) 1 (1.5) 0 (0.0) NS
IMIG (%) 12 (13.6) 5 (7.6) 7 (31.8) NS
IA 17 (19.3) 14 (21.2) 3 (13.6)
IB 37 (42.0) 28 (42.4) 9 (40.9)
II 11 (12.5) 10 (15.2) 1 (4.5)
IIIA 9 (10.2) 8 (12.1) 1 (4.5)
IIIB 2 (2.3) 1 (1.5) 1 (4.5)
Type of surgery (%) <0.001
EPD 52 (59.1) 31 (47.91) 21 (95.5)
EPP 36 (40.9) 35 (53.0) 1 (4.5)
P/D 4 (4.5) 4 (6.1) 0 (0.0)
IMIG, International Mesothelioma Interest Group, (E)PD, extended pleurectomy/decortication; EPP, extrapleural pneumonectomy; P/D, pleurectomy/decortication. Bold, statistically
significant with a p-value <0.05.
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Intraoperative complication rate and postoperative 30-day and
90-day mortality rate was not higher in the patient group
undergoing induction chemotherapy with bevacizumab in
comparison to the control group. Three patients in the control
group and one patient in the bevacizumab group had
intraoperative complications, none due to intraoperative
bleeding. The number of postoperative transfusions of blood
products was statistically different (p=0.047) in the two groups,
with 68.2% of patients in the control group receiving postoperative
blood products including mainly erythrocyte concentrates
compared to 21 patients (95.5%) in the bevacizumab group (see
Table 3). In few cases factor concentrate substitution, fresh frozen
plasma, and thrombocyte concentrates were given as well. The
postoperative hemoglobin, hematocrit, and thrombocyte values
for both groups are shown in Figure 1. A statistically significant
difference between the two groups was seen for hemoglobin values
on POD 1-5, for hematocrit value on POD 5, for erythrocyte
values on POD 2-6, for thrombocyte values on POD 1-6, and for
hematocrit value on POD 1. For all these values, the bevacizumab
group did better, except for the hematocrit value on POD 1.
Additionally, no patient showed major pathological response and
all patient still had microscopically vital tumor tissue in the
definitive pathological tumor specimen.
Postoperative morbidity did not differ between the two
groups with seven (32%) events in the bevacizumab group
compared to 19 (29%) in the control group. Pulmonary
embolism (PE) occurred in six patients in both groups (control
9.1% and bevacizumab group 27.3%; p=0.09). Three patients in
each group had a thromboembolic event after induction therapy
and one patient in each, for both groups, had a thromboembolic
event either before chemotherapy started or after surgery, or after
adjuvant chemo-/radiotherapy. There was no statistically
significant difference in the occurrence of pulmonary embolism
between the two groups in terms of time of occurrence and
number of events. Occurrence of thromboembolic events
according to the surgical procedure was as follow: EPP (n=1
for bevacizumab group vs n=1 for control group), EPD (n=5 vs.
n=3), and P/D (n=0 vs. n=2).
Thirty-day mortality [control group n=1 (1.5%) and
bevacizumab group n=1 (4.5%)] was not statistically different
among the two groups as well as the 90-day mortality [control
group n=4 (6.1%) and n=1 (4.5%, bevacizumab group)].
OS and PFS
At the time point of analysis, 17 patients in the control group and
nine patients in the bevacizumab group were still alive (two lost
to follow up in the control group). Overall median follow up time
was 41 months.
Median OS was 23 months (95% CI: 17.3–33.5) in patients
undergoing induction chemotherapy only and 22.4 months in
patients receiving induction chemotherapy and bevacizumab
(95% CI: 13.5 – not applicable; p = 0.55) with no censored cases.
Median PFS was 11.5 months (95% CI: 11.1–14.5) for the control
group and 11.4 months (95% CI: 10.1–18.2) in the bevacizumab
group. No statistical difference in the two groups was observed in
terms of OS and PFS. OS and PFS are shown in Figure 2.
DISCUSSION
In this propensity score matched retrospective analysis, 22
patients with malignant pleural mesothelioma were treated
with induction chemotherapy consisting of platinum-based/
pem with bevacizumab prior to surgery compared to 66
patients receiving standard induction chemotherapy with
platinum-based/pemetrexed alone. Whereas the concept of a
multimodality treatment is widely accepted and recommended
for this disease, the timing of chemotherapy before or after
surgery is discussed controversially (1, 10, 11) and currently
investigated in a multicenter randomized phase II trial by the
TABLE 3 | Surgery dependent variables.
Covariate Overall Control group Bevacizumab group p-value
n 88 66 22
Blood loss
during surgery (ml, median [range])
1000 [200–5000] 1000 [200–5000] 850 [400–3000] NS
Intraoperative blood products
applied (pack) (%)
32 (36.4) 26 (39.4) 6 (27.3) NS
Intraoperative ECs
applied (ml, median [range])
300 [0–1500] 600 [0–1500] 300 [300–600] NS
Intraoperative
complications n (%)
4 (4.5) 3 (4.5) 1 (4.5) NS
30 Day
Mortality (%)
2 (2.3) 1 (1.5) 1 (4.5) NS
90 Day
Mortality (%)
5 (5.7) 4 (6.1) 1 (4.5) NS
Postoperative hemorrhage
necessitating reoperation (%)
3 (3.4) 2 (3.0) 1 (4.5) NS
Postoperative
morbidities (%)
87 (98.9) 65 (98.5) 22 (100) NS
Postoperative
transfusion of blood products (pack) (%)
66 (75.0) 45 (68.2) 21 (95.5) 0.047
NS, Not statistically significant. Bold, statistically significant with a p-value <0.05.
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EORTC [The European Organization for Research and
Treatment of Cancer (NCT 02436733)].
In the present analysis, adding bevacizumab to standard
induction chemotherapy did not significantly increase
perioperative, in particular not bleeding, complications, although
the proportional number of postoperative blood products and PE
were higher compared to the control group. The small sample size
and the lack of randomization do not allow to draw any
conclusion to fully answer this question as well as the fact that
PE is in general a known side effect of also the other
chemotherapeutic agents. As known in other settings, these data
suggest that a careful monitoring of embolic events in patients
undergoing bevacizumab is warranted.
Bevacizumab is a well-known and potent VEGF inhibitor and
has been mostly used as an additional chemotherapeutic agent,
especially, in solid tumors including malignant mesothelioma, non-
small cell lung cancer, colorectal cancer, renal cancer, and breast
cancer. In malignant pleural mesothelioma patients, anti-VEGF has
already been investigated in several studies for its safety and efficacy
(7, 12). One of the main side effects is an increased risk of bleeding
ranging from minor epistaxis to fatal hemorrhage (7, 13).
Despite evidence of an increased bleeding risk with
bevacizumab, surgery was demonstrated to be safe in our
cohort with negligible intra- and postoperative bleeding
complications and even less intraoperative blood loss (750 ml
vs. 900 ml) in the bevacizumab group, if a time interval of 2–7
weeks after induction chemotherapy, and the exclusion of
bevacizumab in the last cycle prior to surgery, was respected.
By recommendation of the Food and Drug Administration
(FDA), bevacizumab should not be administered less than 28
days before and after a surgical intervention (14).
Numerical wise, in the bevacizumab group, more postoperative
bleeding complications occurred although without statistical
significance compared to the control group. Two cases in the
control group necessitated reoperation due to hemorrhage after
EPP and one case in the bevacizumab group. One hypothesis might
be of a greater postoperative bleeding risk after EPP compared to
(E)PD (8, 15, 16), but the risk for intra- or postoperative bleeding
complications arise from the big bleeding surface after parietal
pleurectomy part (being part of both procedures) (8).
Thirty-day- and 90-day mortality in the bevacizumab group
was very low with one case each compared to the control group
with one and four cases, respectively. The reasons for
postoperative mortality were postoperative empyema, patch
failure with gastric herniation, global respiratory insufficiency
after EPP and necrotizing pancreatitis most probably related to
the surgical procedure itself.
Due to the long observation period, there have been more EPP
performed in the control group than in the (E)PD group. The
learning curve for a better patient selection, the procedures and
complication management might also play a significant role for
the minor postoperative bleeding complication in the EPD/
bevacizumab group. Additionally, preoperative selection criteria
improved over the past years. On restaging imaging by contrast
enhanced CT scan or even PET/CT after induction chemotherapy,
there is a routine assessment of mRECIST, whereby patients are
classified to their tumor response to induction chemotherapy.
A marginal statistically significant difference in terms of a
better response was seen for the bevacizumab group. This
improved response did not translate into a survival benefit.
There have been controversial debates on the efficacy and
overall benefit of bevacizumab treatment, both for single agent use
and for additive use (17–19). Several studies failed to show a clear
benefit in OS or PFS when adding bevacizumab to standard
therapy regimens for patients with malignant pleural
mesothelioma. This may be due to the small sample sizes in the
FIGURE 2 | Overall survival (OS, left figure), red line patients treated with platinum-based/pemetrexed for induction chemotherapy and green line patients treated
with triplet induction chemotherapy including bevacizumab. Median OS in the bevacizumab group 22.4 months (LCL 95%, 13.5, UCL 95%, not applicable). Median
OS in the control group 23 months (LCL 95%, 17.3, UCL 95%, 33.5). Progression free survival (PFS, right figure), red line patients treated with platinum-based/
pemetrexed for induction chemotherapy and green line patients treated with triplet induction chemotherapy including bevacizumab.
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cohorts (17–19). This holds true for our analysis, as PFS and OS in
this cohort did not show a statistically significant improvement
when bevacizumab was added to standard chemotherapy.
Our results are in line with the first randomized double blind
placebo-controlled phase II trial by Kindler et al. where
bevacizumab was added to gemcitabine and cisplatin and both
PFS and OS did not differ statistically significant [PFS of 6.9
months compared to 6.0 months without bevacizumab (p=0.88)
and an OS of 15.6 months compared to 14.7 months, respectively
(p=0.91)] (17).
However, the MAPS trial, the first phase III trial investigated
the addition of bevacizumab to standard chemotherapy regime
proofed the beneficial effect of bevacizumab as the primary
outcome of OS was significantly extended [median OS 18.8
months vs. 16.1 months without bevacizumab (p=0.0167)] (3).
We are aware of the limitations of this studymostly related to the
retrospective nature, even though we performed a 1:3 propensity
score match. Further stratification for more homogenous
distribution of patients in each treatment group was not
applicable due to the limited number of patients treated with
additional bevacizumab and next to the rarity of this disease and
the novel and not yet standardized use of bevacizumab. The
outcomes overall survival, progression free survival, postoperative
morbidity and mortality as well as response to chemotherapy given
as mRECIST may be influenced by potential cofounders in this
propensity score matched analysis. Due to the retrospective nature
of this analysis, there might have been an improvement in patient
management over the time, especially regarding the general learning
curve and a transition from EPP to (E)PD, on top of the lower
mortality rate in the latter group per se, in parallel to the patient
allocation to bevacizumab in the later period.
Themissing impact on overall survival additionally may be due to
this antiangiogenic drug being newly used as an addition to standard
induction chemotherapy (17–19). Secondly, the bevacizumab group
was the one with more patients still alive, this was in the majority
given to the fact, that those were the more recently treated patients.
The scarce statistically significant difference in terms of response was
seen in the bevacizumab group, as well as the missing benefit of
overall survival underlies again that these results must been taken
with caution due to the small sample size.
Despite all these new therapy approaches further trials are
warranted to find an ideal therapy regimen balancing toxicity
and efficacy. Although, increased bleeding risk with bevacizumab
is a known common side effect, mesothelioma surgery can still be
performed safely if appropriate time intervals are respected. We
conclude, this therapy approach, including bevacizumab,
warrants further investigation into a larger number of patients
in order to finally characterize safety and outcome for patients
with mesothelioma.
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